Carnitines Increase Plasma Levels of Adenosine and ATP in Humans

1997 ◽  
Vol 2 (2) ◽  
pp. 77-81 ◽  
Author(s):  
PL Capecchi ◽  
F Laghi Pasini ◽  
E Quartarolo ◽  
T Di Perri
Keyword(s):  
Peripheral Arterial Disease ◽  
Pharmacological Activity ◽  
Plasma Levels ◽  
Mode Of Action ◽  
Peak Plasma ◽  
Arterial Disease ◽  
Physiological Mechanisms ◽  
Tissue Protection ◽  
Peripheral Arterial ◽  
Carnitine Derivatives

In order to help to clarify the mode of action of carnitine derivatives, plasma levels of adenosine, ATP and inosine were evaluated following the infusion of 0.75, 0.50 and 0.25 mg/kg/min propionyl-L-carnitine (PLC) for 30 min in patients affected with peripheral arterial disease. Moreover, the effects of 0.75 mg/kg/min acetyl-L-carnitine (ALC) and L-carnitine (LC) were studied in the same conditions. Finally, the activity of 7.5 mg/kg/min PLC administered for 3 min was also evaluated. PLC and ALC produced a significant increase in plasma levels of adenosine and ATP, whereas LC induced less relevant changes. The administration of the compounds did not affect the adenosine/inosine ratio. Peak plasma levels of adenosine preceded in any case those of ATP. The possibility can be suggested that the pharmacological activity of PLC, ALC, and LC may be mediated, at least in part, by an interference with the endogenous purine system. Since these effects may be related to physiological mechanisms of tissue protection, new pharmacological perspectives for the compounds may arise.

scholarly journals Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease

2005 ◽  
Vol 10 (1) ◽  
pp. 1-6 ◽  
Author(s):  
Salvatore Santo Signorelli ◽  
Grazia Malaponte ◽  
Massimo Libra ◽  
Luigi Di Pino ◽  
Gabriella Celotta ◽  
...  
Keyword(s):  
Matrix Metalloproteinases ◽  
Peripheral Arterial Disease ◽  
Plasma Levels ◽  
Arterial Disease ◽  
Type Ii ◽  
Type Ii Diabetics ◽  
Peripheral Arterial

Mode of action of prostaglandin E1 in the treatment of peripheral arterial disease

VASA ◽  
2003 ◽  
Vol 32 (4) ◽  
pp. 187-192 ◽  
Author(s):  
Weiss
Keyword(s):  
Peripheral Arterial Disease ◽  
Mode Of Action ◽  
Prostaglandin E1 ◽  
Arterial Disease ◽  
Prostaglandin E ◽  
Peripheral Arterial

Obwohl Prostaglandin E1 vor 30 Jahren erstmals zur Therapie schwerer peripherer Durchblutungsstörungen eingesetzt wurde, ist der genaue Wirkmechanismus nicht bekannt. Die intraarterielle Anwendung von PGE1 induziert eine ausgeprägte Vasodilatation, die nach intravenöser Infusion nicht eintritt. Bei der nachgewiesenen klinischen Wirksamkeit von intravenös verabreichtem PGE1 kann die Vasodilation nicht als entscheidendes Wirkprinzip betrachtet werden. Multiple Effekte von PGE1 auf die korpuskulären Bestandteile des Blutes, Hämostase und Fibrinolyse sowie Endothel sind mittlerweile bekannt. In der vorliegenden Arbeit werden einige dieser Wirkmechanismen vorgestellt und diskutiert.

scholarly journals Relationship between the Plasma Concentration of C-Reactive Protein and Severity of Peripheral Arterial Disease

2009 ◽  
Vol 3 ◽  
pp. CMC.S1062 ◽  
Author(s):  
Joaquin De Haro ◽  
Francisco Acin ◽  
Francisco Jose Medina ◽  
Alfonso Lopez-Quintana ◽  
Jose Ramon March
Keyword(s):  
Peripheral Arterial Disease ◽  
Plasma Levels ◽  
Smoking Status ◽  
Arterial Disease ◽  
Clinical Severity ◽  
C Reactive Protein ◽  
Surgical Revascularization ◽  
Reactive Protein ◽  
Markers Of Inflammation ◽  
Peripheral Arterial

Objective To determine whether the increase in plasma levels of C-Reactive Protein (CRP), a non-specific reactant in the acute-phase of systemic inflammation, is associated with clinical severity of peripheral arterial disease (PAD). Methods and Results This is a cross-sectional study at a referral hospital center of institutional practice in Madrid, Spain. A stratified random sampling was done over a population of 3370 patients with symptomatic PAD from the outpatient vascular laboratory database in 2007 in the order of their clinical severity: the first group of patients with mild chronological clinical severity who did not require surgical revascularization, the second group consisted of patients with moderate clinical severity who had only undergone only one surgical revascularization procedure and the third group consisted of patients who were severely affected and had undergone two or more surgical revascularization procedures of the lower extremities in different areas or needed late re-interventions. The Neyman affixation was used to calculate the sample size with a fixed relative error of 0.1. A homogeneity analysis between groups and a unifactorial analysis of comparison of medians for CRP was done. The groups were homogeneous for age, smoking status, Arterial Hypertension HTA, diabetes mellitus, dyslipemia, homocysteinemia and specific markers of inflammation. In the unifactorial analysis of multiple comparisons of medians according to Scheffe, it was observed that the median values of CRP plasma levels were increased in association with higher clinical severity of PAD (3.81 mg/L [2.14-5.48] vs. 8.33 [4.38-9.19] vs. 12.83 [9.5-14.16]; p < 0.05) as a unique factor of tested ones. Conclusion Plasma levels of CRP are associated with not only the presence of atherosclerosis but also with its chronological clinical severity.

Adhesion molecules and cardiovascular risk in peripheral arterial disease

2005 ◽  
Vol 93 (03) ◽  
pp. 559-563 ◽  
Author(s):  
Vittorio Schiano ◽  
Francesco Scopacasa ◽  
Massimo Chiariello ◽  
Antonio Silvestro ◽  
Gregorio Brevetti
Keyword(s):  
Cardiovascular Risk ◽  
Peripheral Arterial Disease ◽  
Adhesion Molecule ◽  
Cardiovascular Event ◽  
Plasma Levels ◽  
Ankle Brachial Index ◽  
Arterial Disease ◽  
Prognostic Impact ◽  
Risk Indicator ◽  
Peripheral Arterial

SummaryAlthough intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) play a relevant role in atherosclerosis, little is known about the prognostic impact of their soluble forms (s) in patients with peripheral arterial disease (PAD). The aim of this prospective study was to verify whether plasma levels of s ICAM-1 and s VCAM-1 predict cardiovascular risk in PAD, and improve the prognostic value of the ankle/brachial index (ABI) alone. Accordingly, plasma levels of sICAM-1 and sVCAM-1, and the ABI were measured in 75 PAD patients who were monitored for a mean of 24±13 months. Twenty-two (29.3%) patients had a cardiovascular event (15 coronary, 3 cerebrovascular and 4 peripheral events). Plasma levels of sVCAM-1 were 618±258 ng/mL in patients with and 496±164 ng/mL in those without an event (p= 0.016). The corresponding sICAM-1 values were 344±239 ng/mL and 275±99 ng/mL (p= 0.079). The cardiovascular event rate was higher in patients with sVCAM-1 levels above the median than in those with sVCAM-1 below the median (p=0.0027 by log rank test). Independent predictors of events were sVCAM-1 levels above the median (p=0.005) and an ABI below the median (p= 0.001). Amongst patients with ABI below the median, the occurrence of sVCAM-1 above the median was associated with a 3.4-fold increase in risk (95% CI 1.308 to 9.573, p= 0.013). In conclusion, increased plasma levels of sVCAM-1 have a negative prognostic impact in PAD and improve the predictive value of ABI, which is currently the most powerful risk indicator in these patients.

Plasma Levels of Inflammatory Biomarkers in Peripheral Arterial Disease

Angiology ◽  
2016 ◽  
Vol 67 (9) ◽  
pp. 870-874 ◽  
Author(s):  
Salvatore Santo Signorelli ◽  
Massimiliano Anzaldi ◽  
Massimo Libra ◽  
Patrick M. Navolanic ◽  
Graziella Malaponte ◽  
...  
Keyword(s):  
Peripheral Arterial Disease ◽  
Plasma Levels ◽  
Arterial Disease ◽  
Inflammatory Biomarkers ◽  
Peripheral Arterial
Sign in / Sign up

Export Citation Format

Share Document